PMID- 36706520
OWN - NLM
STAT- MEDLINE
DCOM- 20230320
LR  - 20230328
IS  - 1096-3618 (Electronic)
IS  - 1044-5323 (Linking)
VI  - 66
DP  - 2023 Mar
TI  - Viral T-cell epitopes - Identification, characterization and clinical 
      application.
PG  - 101725
LID - S1044-5323(23)00016-7 [pii]
LID - 10.1016/j.smim.2023.101725 [doi]
AB  - T-cell immunity, mediated by CD4(+) and CD8(+) T cells, represents a cornerstone 
      in the control of viral infections. Virus-derived T-cell epitopes are represented 
      by human leukocyte antigen (HLA)-presented viral peptides on the surface of 
      virus-infected cells. They are the prerequisite for the recognition of infected 
      cells by T cells. Knowledge of viral T-cell epitopes provides on the one hand a 
      diagnostic tool to decipher protective T-cell immune responses in the human 
      population and on the other hand various prophylactic and therapeutic options 
      including vaccination approaches and the transfer of virus-specific T cells. Such 
      approaches have already been proven to be effective against various viral 
      infections, particularly in immunocompromised patients lacking sufficient 
      humoral, antibody-based immune response. This review provides an overview on the 
      state of the art as well as current studies regarding the identification and 
      characterization of viral T-cell epitopes and approaches of clinical application. 
      In the first chapter in silico prediction tools and direct, mass 
      spectrometry-based identification of viral T-cell epitopes is compared. The 
      second chapter provides an overview of commonly used assays for further 
      characterization of T-cell responses and phenotypes. The final chapter presents 
      an overview of clinical application of viral T-cell epitopes with a focus on 
      human immunodeficiency virus (HIV), human cytomegalovirus (HCMV) and severe acute 
      respiratory syndrome coronavirus type 2 (SARS-CoV-2), being representatives of 
      relevant viruses.
CI  - Copyright (c) 2023. Published by Elsevier Ltd.
FAU - Schroeder, Sarah M
AU  - Schroeder SM
AD  - Department of Peptide-based Immunotherapy, University and University Hospital 
      Tubingen, Tubingen, Germany; Department for Otorhinolaryngology, Head, and Neck 
      Surgery, University Hospital Tubingen, Tubingen, Germany; Institute for Cell 
      Biology, Department of Immunology, University of Tubingen, Tubingen, Germany.
FAU - Nelde, Annika
AU  - Nelde A
AD  - Department of Peptide-based Immunotherapy, University and University Hospital 
      Tubingen, Tubingen, Germany; Institute for Cell Biology, Department of 
      Immunology, University of Tubingen, Tubingen, Germany; Cluster of Excellence iFIT 
      (EXC2180) 'Image-Guided and Functionally Instructed Tumor Therapies', University 
      of Tubingen, Tubingen, Germany.
FAU - Walz, Juliane S
AU  - Walz JS
AD  - Department of Peptide-based Immunotherapy, University and University Hospital 
      Tubingen, Tubingen, Germany; Institute for Cell Biology, Department of 
      Immunology, University of Tubingen, Tubingen, Germany; Cluster of Excellence iFIT 
      (EXC2180) 'Image-Guided and Functionally Instructed Tumor Therapies', University 
      of Tubingen, Tubingen, Germany; Clinical Collaboration Unit Translational 
      Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, 
      University Hospital Tubingen, Tubingen, Germany. Electronic address: 
      juliane.walz@med.uni-tuebingen.de.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20230125
PL  - England
TA  - Semin Immunol
JT  - Seminars in immunology
JID - 9009458
RN  - 0 (Epitopes, T-Lymphocyte)
RN  - 0 (Histocompatibility Antigens Class I)
SB  - IM
MH  - Humans
MH  - *CD8-Positive T-Lymphocytes
MH  - Epitopes, T-Lymphocyte
MH  - *COVID-19
MH  - SARS-CoV-2
MH  - Histocompatibility Antigens Class I
OTO - NOTNLM
OT  - DC vaccination
OT  - Immunopeptidomics
OT  - In silico prediction
OT  - Mass spectrometry
OT  - Peptide vaccination
OT  - T-cell assays
OT  - T-cell epitope characterization
OT  - T-cell epitopes
OT  - T-cell transfer
OT  - Viral infection
COIS- Declaration of Competing Interest A.N. and J.S.W. are listed as inventors on 
      patent applications of the COVID-19T cell activator CoVac-1, application number: 
      PCT/EP 20 190 070.1 and of SARS-CoV-2 CD8+ und CD4+ T cell epitopes, Application 
      number: PCT/EP 20 169 047.6. A.N. is listed as inventor on a patent application 
      of HCMV-derived peptides, application number: EP2020/074114. The other author 
      declares no competing interests.
EDAT- 2023/01/28 06:00
MHDA- 2023/03/21 06:00
CRDT- 2023/01/27 18:07
PHST- 2022/10/01 00:00 [received]
PHST- 2023/01/16 00:00 [revised]
PHST- 2023/01/17 00:00 [accepted]
PHST- 2023/01/28 06:00 [pubmed]
PHST- 2023/03/21 06:00 [medline]
PHST- 2023/01/27 18:07 [entrez]
AID - S1044-5323(23)00016-7 [pii]
AID - 10.1016/j.smim.2023.101725 [doi]
PST - ppublish
SO  - Semin Immunol. 2023 Mar;66:101725. doi: 10.1016/j.smim.2023.101725. Epub 2023 Jan 
      25.